Tests that detect Mycobacterium tuberculosis antigens in clinical specimens could provide rapid direct evidence of active disease. We performed a systematic review to assess the diagnostic accuracy of antigen detection tests for active tuberculosis (TB) according to standard methods and summarized test performance using bivariate random effects meta-analysis. Overall, study quality was a concern. For pulmonary TB (47 studies, 5,036 participants), sensitivity estimates ranged from 2% to 100% and specificity from 33% to 100%. Lipoarabinomannan (LAM) was the antigen most frequently targeted (23 studies, 49%). The pooled sensitivity of urine LAM was higher in HIV-infected than HIV-uninfected individuals (47%; 95% confidence interval [CI], 26 to 68% versus 14%; 95% CI, 4 to 38%); pooled specificity estimates were similar: 96%; 95% CI, 81 to 100% and 97%; 95% CI, 86 to 100%, respectively. For extrapulmonary TB (21 studies, 1,616 participants), sensitivity estimates ranged from 0% to 100% and specificity estimates from 62% to 100%. Five studies targeting LAM, ESAT-6, Ag85 complex, and the 65-kDa antigen in cerebrospinal fluid, when pooled, yielded the highest sensitivity (87%; 95% CI, 61 to 98%), but low specificity (84%; 95% CI, 60 to 95%). Because of the limited number of studies targeting any specific antigen other than LAM, we could not draw firm conclusions about the overall clinical usefulness of these tests. Further studies are warranted to determine the value of LAM detection for TB meningitis in high-HIV-prevalence settings. Considering that antigen detection tests could be translated into rapid point-of-care tests, research to improve their performance is urgently needed.
The World Health Organization (WHO) estimates that in 2009, 9.4 million new cases of tuberculosis (TB) occurred and 1.7 million people died of the disease (89) . The vast majority of these patients live in low-and middle-income countries (LMIC) where TB diagnosis depends primarily on smear microscopy. Microscopy has low sensitivity and does not detect smear-negative TB (77) , which may account for 24% to 61% of all pulmonary cases in HIV-infected individuals (27) . Improved diagnostic tests, such as mycobacterial culture and nucleic acid amplification (NAA) tests, are available in highincome countries but are often too expensive and complex for routine use by TB control programs in resource-constrained settings in which TB is endemic. Lack of access to diagnostic services in resource-limited settings presents an additional barrier to using these tests. The Xpert MTB/RIF (Cepheid, Inc., Sunnyvale, CA), recently endorsed by the WHO, is rapid and highly sensitive for detection of TB and drug resistance; however, this new technology is costly, preventing its use in many areas where the epidemic is most severe (10) . Accurate, rapid, inexpensive, and simple diagnostic tests are urgently needed for TB care and control.
There have been considerable efforts over the past 50 years to devise a rapid TB test based on antibody detection. However, substantial published evidence suggests that current commercial serological tests are inaccurate for diagnosis of active TB (22, (73) (74) (75) (76) 91) . A meta-analysis of noncommercial serological tests identified several potential candidate antigens and antigen combinations for inclusion in an antibody detection test for pulmonary TB (PTB) (73) . Recently, serological profiling of the complete Mycobacterium tuberculosis proteome has been described (38) . In July 2011, the WHO issued a policy statement against the use of commercial serological tests for the diagnosis of active pulmonary and extrapulmonary TB (EPTB) while stressing the importance of continued research on antibody-based detection tests and point-of-care tests (90) .
Another approach aims to detect circulating mycobacterial antigens in clinical specimens such as serum, sputum, urine, cerebrospinal spinal fluid (CSF), and pleural fluid. A common design for antigen detection tests is the sandwich enzymelinked immunosorbent assay (ELISA) technique, also called the antigen-capture ELISA, described in Fig. 1 . Another format is the lateral-flow immunochromatographic assay, sometimes referred to as a dipstick. In one common scheme of this technique, the antigen is initially introduced onto the device by adding a sample from a clinical specimen, such as urine or serum. Free antigen, if present, binds to an antibody/microsphere (bead) complex, providing a visually detectable color change (44) . Dipsticks require little and sometimes no sample processing. Agglutination is an alternate method that can detect antigens when they clump together (agglutinate) with antibodies and form a visual complex.
In comparison with conventional diagnostics, antigen detection tests appear to offer several advantages. Immunochromatographic tests, for example, are rapid (results may be available within minutes) and easy to operate. If developed into a point-of-care test, an antigen detection test could extend TB diagnosis to remote health posts. Antigen detection tests provide direct evidence of active disease, thus allowing for immediate initiation of TB treatment. An antigen detection test using a specimen such as urine would be particularly attractive with children, who may have difficulty providing sputum. Finally, in patients suspected of extrapulmonary TB, an antigen detection test might prevent the use of more invasive tests.
To our knowledge, two systematic reviews have previously assessed the diagnostic accuracy of antigen detection tests for TB (22, 45) . Both reviews reported on the performance of tests targeting lipoarabinomannan (LAM), a major glycolipid component of the cell wall of M. tuberculosis and other mycobacteria (12, 30) . The first review identified one study evaluating sputum LAM; the sensitivity was 63%, and the specificity 92% (22) . The second review focused on urine LAM (9 studies) (45) . Depending on the classification of culture-negative clinical TB, pooled sensitivity estimates ranged from 34% to 60% and pooled specificity from 93% to 94%. Two recent narrative reviews were also identified (16, 55) . However, one review focused only on urine-based tests (55) , and neither review appraised study quality or performed a meta-analysis.
The objective of the current systematic review is to estimate the diagnostic accuracy of antigen detection tests using different clinical specimens for PTB and EPTB in adults and children with and without HIV infection.
MATERIALS AND METHODS
We followed methods for conducting and reporting systematic reviews and meta-analyses recommended by the Cochrane Collaboration Diagnostic Test Accuracy Working Group and the PRISMA statement, including the preparation of a protocol (26, 40, 46) . Selection criteria and definitions. (i) Types of studies. Included were diagnostic studies (with any study design) that evaluated antigen detection tests (using immunologic methods such as a sandwich ELISA) for PTB and EPTB in patients providing clinical specimens prior to or within 14 days of starting antituberculous treatment.
(ii) Participants. Participants included adults and children with suspected or confirmed active TB (at least 10 cases), with or without HIV infection.
(iii) Intervention (test). The tests consisted of an antigen detection test using an immunologic method, such as a sandwich ELISA or immunochromatographic assay.
(iv) Target conditions. Target conditions consisted of pulmonary TB and extrapulmonary TB.
(v) Reference standards. Positivity on culture was used for PTB and positivity on culture, smear, or histopathological examination for EPTB. For TB meningitis, we accepted positivity by commercial NAA tests because these tests provide high specificity (22, 51) .
(vi) Outcomes. Sensitivity refers to the proportion of patients among TB patients with a positive antigen detection test result confirmed by the reference standard. Specificity refers to the proportion of non-TB participants with a negative antigen detection test result among non-TB participants. To estimate specificity, we selected only one non-TB group if a study had more than one such group. The preferred non-TB participants were those in whom active TB was initially suspected but later ruled out ("other respiratory disease" or "other disease" groups) and who were from the same population as TB patients.
EPTB was classified as lymph node, pleural, meningeal, and/or central nervous system, bone and/or joint, genitourinary, abdominal, skin, other site, disseminated, and multiple (extrapulmonary TB cases from different sites are combined to obtain at least 10 extrapulmonary TB cases).
Countries were classified as high income or LMIC according to the World Bank list of economies (88) .
The following were excluded: (i) studies published before 1990, (ii) animal studies, (iii) conference abstracts and proceedings, (iv) studies of the detection of latent TB infection, (v) studies of the detection of nontuberculous mycobacteria, and (vi) basic science literature focused on the detection/cloning of new antigens or evaluation of their immunological properties (i.e., early preclinical studies). VOL. 18, 2011 META-ANALYSIS OF ANTIGEN DETECTION TESTS FOR TBcriteria, independently reviewed full-text articles. Disagreements about study selection were resolved by discussion between the reviewers. Data extraction. A data extraction form was created, pilot tested with a subset of eligible studies, and then finalized. Two reviewers (L.L.F. and K.R.S.) independently extracted data from the included studies with the standardized form on the following characteristics: study design, age group (children Ͻ 15 years), HIV status, country, smear status, form of TB, assay type, test name, antigen identity, type of specimen, sensitivity, and specificity. When possible, studies were classified by HIV or smear status. Differences between reviewers concerned mainly methodological quality and were resolved by discussion. When necessary, authors were contacted for additional information.
We looked for information on patient-important outcomes, such as mortality, time to diagnosis, and number of patient visits during the diagnostic process.
Assessment of methodological quality. Two reviewers independently assessed study quality using QUADAS (Quality Assessment of Diagnostic Accuracy Studies), a validated tool to evaluate the presence of bias in diagnostic accuracy studies (86) (see supplemental material S2).
Data analysis. Descriptive analyses were performed using SPSS (version 14.0.1.366). For each study, the sensitivity and specificity of the test along with 95% confidence intervals (CI) were calculated, and forest plots created to display the estimates using Review Manager 5.1 (the Nordic Cochrane Center, Copenhagen, Denmark). Heterogeneity was assessed by visual examination of forest plots.
Selection of subgroups for meta-analysis. Heterogeneity was addressed by prespecifying subgroups by type of specimen evaluated, antigen(s) detected, and smear and HIV status (see Fig. S1 in the supplemental material). For the meta-analysis, at least four studies for inclusion in a subgroup were required.
Bivariate meta-analyses that jointly modeled both sensitivity and specificity were performed. These models weighted studies according to the sampling variability within studies as well as the unexplained heterogeneity between studies using a random effects approach (63) . The model was estimated using a Bayesian approach with nonsubjective prior distributions and implemented using WinBUGS (version 1.4.1) (71). The meta-analysis provides a pooled estimate of the sensitivity and specificity across studies. A hierarchical summary receiver operating characteristic (HSROC) plot provides added information when there is high heterogeneity between studies, and the pooled estimate may not be representative of all studies. The HSROC curve plots sensitivity versus specificity and provides information on the overall performance of a test across different thresholds. The closer the curve is to the upper left hand corner of the plot (sensitivity and specificity are both 100%), the better is the performance of the test. The plots were made using R (version 2.6.1) (58).
RESULTS
Initially, 8,263 citations were identified (Fig. 2) . After screening titles and abstracts, 132 potentially relevant full-text articles were retrieved; 49 publications describing a total of 68 studies (47 for PTB and 21 for EPTB) were selected for inclusion in the review. A list of excluded articles with reasons for exclusion is available upon request from the authors.
PTB. (i) Characteristics of included studies. Thirty papers, 29 in English (1, 2, 5, 6, 8, 9, 14, 15, 17-20, 23, 33, 37, 39, 43, 49, 50, 54, 57, 60, 61, 64, 66, 67, 70, 72, 85 ) (2 papers by Shah et al. concerned the same investigation) and one in French (24), were included ( Table 1) . The 47 PTB studies involved 5,036 participants (sample size ϭ 6,540). The majority (81%) of the studies were conducted in LMIC. Eight studies involved HIV-infected individuals; none involved children. In each study, all non-TB participants were from the same country as TB patients. Twenty-three (49%) studies had a cross-sectional design, and 21 (45%) studies a case-control design. In three Table 2 , single antigens were targeted in 24 (51%) studies and multiple antigens in 21 studies; the number of antigens was not reported in two studies. Of the 47 studies, LAM was the antigen most frequently targeted, either as a single antigen or one of several antigens (23 studies, 49%). Among the 20 studies targeting LAM alone, urine was the specimen most often evaluated (14 studies). In 15 (32%) studies, antigen identity was not reported. Five commercial tests were evaluated, accounting for 25 (53%) of the total studies: Patho-TB (Anda Biologicals, France; 4 studies), Diagnos TB Ag (Biomed Industries, India; 3 studies), LAM-ELISA (Chemogen, United States; 10 studies [this assay was a precommercial prototype and the test is no longer available]), Clearview TB ELISA (Inverness Medical Innovations, United States; 6 studies), and a latex agglutination test for TB (Wellcome Diagnostics, United Kingdom; 2 studies).
As assessed with QUADAS, all studies satisfied six quality items: acceptable reference standard (a criterion for inclusion in the review), acceptable delay between tests, partial verification avoided, incorporation avoided, reference standard results blinded (as the culture result was considered to be entirely objective in interpretation), and relevant clinical information. However, studies had serious shortcomings in two essential items, representative spectrum (selection of a representative patient population) and blinding, factors that have been shown empirically to be associated with exaggerated accuracy estimates (42): only 18 (38%) studies involved a representative patient population and only 19 (40%) reported blinding of the result of the antigen detection test (see Fig. S2 in the supplemental material). Figure 3 is a forest plot of the sensitivity and specificity of individual studies stratified by specimen type. There was considerable heterogeneity within strata (for example, within the serum subgroup, sensitivity ranged from 28% to 100%). Estimated sensitivity ranged from 2% to 100%, and specificity from 33% to 100% across studies. Similar ranges of performance (sensitivity of 6% to 100% and specificity of 33% to 100%) were seen when the analysis was restricted to studies from LMIC (data not shown).
(ii) Urine LAM studies of HIV-infected and uninfected TB patients. As shown in Fig. 4 , five studies reported the performance of urine LAM in individuals with TB-HIV coinfection; four of these studies reported data comparing LAM antigen detection in individuals with and without HIV infection. All four studies found improved sensitivity in HIV-infected compared with HIV-uninfected individuals (14% to 53% higher sensitivity), although in three studies, specificity was lower by 6% to 7%, and in one study, specificity was increased by 1%. In three studies involving HIV-TB-coinfected patients, results were stratified by CD4 cell count (20, 39, 67) . All three studies found a higher sensitivity of urine LAM in patients with lower CD4 cell counts. We identified only one study that evaluated urine LAM in sputum smear-negative HIV-infected individuals. Sensitivity was 42%, with a 95% CI of 20 to 67%, and specificity was 84%, with a 95% CI of 68 to 94% (60).
Lawn et al. found that only 2 h were required for detection of LAM in urine compared with an average of 24 days for detection of M. tuberculosis complex by culture (39) . In addition, five of 22 patients at risk for paradoxical TB immune 
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reconstitution disease had detectable LAM. The authors noted a trend toward increased mortality in patients with LAM positivity, although this trend was not statistically significant (39) .
(iii) Meta-analysis of studies of PTB. Among the 47 studies of PTB patients, there was considerable heterogeneity in specimen type, antigen identity, and smear and HIV status. We were able to identify five subgroups that were more homogeneous (Tables 3 and 4 ). For sputum LAM (studies of both smear-positive and -negative patients), the pooled sensitivity for LAM was 87%, with a 95% CI of 71 to 96%, and the pooled specificity 70%, with a 95% CI of 6 to 99% (Table 3) . For urine LAM, the performances were similar in smear-positive (pooled sensitivity, 54%, and 95% CI, 18 to 86%; pooled specificity, 90%, and 95% CI, 83 to 95%) and smear-negative (pooled sensitivity, 51%, and 95% CI, 18 to 83%; pooled specificity, 90%, and 95% CI, 79 to 96%) patients (Table 4) . Within studies of HIV-uninfected TB patients (n ϭ 4), the pooled sensitivity of urine LAM was 14%, with a 95% CI of 4 to 38%, and the pooled specificity was 97%, with a 95% CI of 86 to 100%. In HIV-infected TB patients, the pooled sensitivity was higher but still low (n ϭ 5, 47%; 95% CI, 26 to 68%), and pooled specificity similar (96%; 95% CI, 81 to 100%) ( Table  5 ). The estimated probability that the pooled sensitivity of the test with HIV-infected patients exceeds that of the test with HIV-uninfected patients was 98%.
EPTB. (i) Characteristics of included studies. All 19 articles were written in English (4, 6, 13, 21, 29, 32, 34, 35, 47, 48, 52, 53, 56, 66, 68, 69, 82, 84, 87) (Table 5 ). The 21 EPTB studies involved 1,616 participants (sample size ϭ 1,690). The majority (91%) of studies were conducted in LMIC. In four studies, HIV-infected individuals comprised 49% (21), 68% (52), 84% (53) , and 85% (67) of the total enrolled patients. The remaining papers did not report HIV status. No studies involved children. In each study, all non-TB participants were from the same country as TB patients. The median number of TB patients included in each study was 22 (interquartile range of 14 to 31). Seventeen (81%) studies involved in-house tests, and four used the Clearview TB ELISA. Of the total 21 studies, 14 (64%) used the ELISA, 2 (9%) an agglutination test, and 5 immunohistochemical staining of biopsy specimens. In seven (33%) studies, the targeted antigen was unspecified.
Overall, studies had serious limitations: only three (14%) studies were considered to involve a representative patient population and only nine (43%) reported blinding of the antigen detection test result, (see Fig. S3 in the supplemental material). Figure 5 is a forest plot of the sensitivity and specificity of individual studies stratified by specimen type. There was considerable heterogeneity within strata (for example, within the biopsy specimen subgroup, sensitivity ranged from 36% to 100%). The estimated sensitivity for all studies ranged from 0% to 100%, and specificity from 62% to 100%. In the EPTB group, no studies reported patientimportant outcomes.
(ii) Meta-analysis of studies of EPTB. Among the 21 studies of EPTB patients, there was considerable heterogeneity in disease site, specimen type, and antigen identity. We were able to identify three subgroups that were homogenous in terms of specimen type: serum, CSF, and biopsy specimen (Table 3) . Studies targeting LAM, ESAT-6, Ag85 complex, and the 65-kDa antigen (65-kDa) in CSF, when pooled, yielded the highest sensitivity (87%; 95% CI, 61 to 98%), but low specificity (84%; 95% CI, 60 to 95%) ( Table 3 ; Fig. 6 ). b Antigens detected: LAM (n ϭ 2); Ag85complex (Rv3804c and Rv1886c, n ϭ 1); ESAT-6 early secreted antigenic target-6 (Rv3875, n ϭ 1); 65 kDa (Rv0440, n ϭ 1). Pooled accuracy estimates are based on 5 studies with defined antigen targets. When data from an additional study targeting "nonspecific glycolipid antigens" were included (82), pooled sensitivity was 90% (56 to 99%) and pooled specificity 86% (72 to 94%).
c Antigens were unspecified in all studies.
DISCUSSION
Forty-seven PTB and 21 EPTB studies evaluating antigen detection tests for the diagnosis of TB were included in this systematic review. Eight subgroups comprising 37 studies were selected for meta-analysis. Within these subgroups, for both PTB and EPTB, sensitivity and specificity were variable. At a recent meeting convened by Médecins Sans Frontières, Partners in Health, and the Treatment Action Group, a multidisciplinary group of TB experts, including clinicians, test developers, laboratory experts, research scientists, and community representatives, proposed a set of minimal specifications for a point-of-care test based on modeling and expert opinion: in adults with pulmonary TB, the test should achieve a sensitivity of 95% in smear-positive and 60% to 80% in smear-negative cases and a specificity of 95%; and in extrapulmonary TB, the test should provide a sensitivity of 80% and specificity of 95% (41) . In this review, for both PTB and EPTB, pooled accuracy estimates in all analyses fell short of achieving the required sensitivity and specificity values. However, we caution that our meta-analyses are based on a small number of studies, meaning that there is still considerable uncertainty in the usefulness or lack of usefulness of these tests. A new TB test may have several purposes, for example, triage, replacement test for microscopy, or add-on test following microscopy. Although we did not identify any studies that specifically considered the added value of antigen detection tests in addition to microscopy, in such a scenario, the required sensitivity for smearpositive patients may not need to be that great or necessarily higher than that for smear-negative patients. LAM was the most frequently studied antigen, probably because it is a major constituent of the mycobacterial cell wall (12, 30) , and a commercial LAM test has been developed. Although in this review the sensitivity of LAM detection was higher in sputum (87%) than urine (53%), urine LAM has important implications. First, it provides proof of principle that antigen detection with an easily obtained specimen can be exploited to develop a TB diagnostic test. Second, our metaanalysis demonstrates that urine LAM provides higher sensitivity in HIV-infected (47%) compared with HIV-uninfected (14%) TB patients, as was also found in a recent systematic review of urine LAM for TB (45) . One possible explanation may be that the former set of patients has a higher or more disseminated bacterial burden with LAM antigenemia, leading to detectable LAM in urine. Of note, LAM positivity appeared to be inversely related to the CD4 count. Third, recent studies evaluating NAA tests with multiple specimens from the same patients have shown that this strategy increases the sensitivity of bacterial detection (59) , suggesting that evaluation of both sputum and urine from the same patient may provide higher sensitivity than either specimen alone. Fourth, although in HIV-infected individuals we found the sensitivity of urine LAM for pulmonary TB to be relatively low, the combination of LAM testing and smear microscopy may provide additional benefit as proposed by Shah and colleagues (66) . Although pooled specificity of urine LAM was relatively high (Ն96%), specificity was found to be low (84% to 94%) in several studies and even lower in studies of serum and sputum LAM. Possible reasons include the presence of latent TB infection, misclassification of subclinical TB cases, or cross-reactivity with nontuberculous mycobacteria (3, 28, 30, 36) . Studies are now required to clarify the cause of reduced LAM specificity.
For EPTB, the highest pooled sensitivity was achieved in tests for TB meningitis, a condition that is challenging to diagnose. Microscopy has poor sensitivity (ϳ5%) for TB meningitis, and culture takes several weeks for results (80) . Commercial NAA tests show high specificity (98%) and low and variable sensitivity (approximately 60%), require technical skill, and are expensive (51) . With reported fatality rates above 50% (81), even a modest improvement in the accurate diagnosis of TB meningitis would be valuable. Two studies evaluating CSF LAM were well designed and reported (52, 53) . Both involved a high proportion (Ͼ60%) of HIV-infected TB patients and achieved sensitivities of approximately 65%, suggesting that CSF LAM might be useful as a rule-in test for the rapid diagnosis of TB meningitis in high-HIV-prevalence settings. A point-of-care version of a LAM detection test for TB meningitis might be good to explore, especially if the test combined detection of LAM and other promising biomarkers, such as gamma interferon and adenosine deaminase (22, 83, 92) .
Antigen detection tests for TB will require identification of antigens that have the following properties: abundant expression by in vivo bacteria, presence of antigens in the extracellular environment, and resistance to degradation by the enzymes that may be released during the inflammatory responses of the host. Moreover, antigens that are specific to M. tuberculosis will likely be necessary. Considering that M. tuberculosis adapts to its environment by modifying its transcriptional responses (25, 65, 78) , it is not unreasonable to assume that the optimal antigens or antigen combinations for diagnosing different forms of EPTB may vary. Antigen detection in serum may be more difficult due to complex formation with the antibodies they elicit. The feasibility of using antigen detection tests for paucibacillary TB is unclear, but tests that detect multiple antigens may yield higher sensitivities than tests that detect single antigens. Besides LAM, no other antigens with potential value were identified in this review.
The strengths of our review include the use of standard guidelines, a comprehensive search strategy, two independent reviewers for all stages of the review process, and quality assessment with QUADAS. Although heterogeneity between diagnostic accuracy studies is to be expected (31), we attempted to address heterogeneity by prespecifying similar subgroups and by using a bivariate meta-analysis method.
Our review had limitations. The meta-analysis was limited by the small number of studies of any particular antigen detection test, with the exception of LAM. Our review did not account for different specimen processing techniques that may have contributed to variability in test performance. For example, 16 (80%) of the total 20 studies evaluating sputum used a processing method (studies differed with respect to the chemicals used and duration and gravitational force/speed of centrifugation), one study did not use a processing method, and three studies did not report whether or not a processing method was used. In studies evaluating urine LAM, two tests, the LAM-ELISA and the Clearview TB ELISA, were used. Although these assays contain the same polycolonal antibodies, the manufacturing processes differ; factors such as pH and viscosity may have affected diagnostic accuracy. In a systematic review of urine LAM for active TB, there was no statistically significant difference in performance noted between the groups of studies using fresh and previously frozen urine (45) . In about 30% of the studies, test performance was reported, but antigen identity was unspecified. We were limited in our assessment of study quality by incomplete reporting of information. We encourage investigators to be more transparent about their studies. Publication bias is possible because studies with poor performance were unlikely to be unpublished. Statistical tests, such as funnel plots, are not recommended to detect potential publication bias in meta-analyses of diagnostic data (79) . Accuracy estimates in our meta-analysis may be exaggerated because of the risk of bias from the selection of unrepresentative samples and lack of blinding (42, 62) . The small sample size of individual studies contributes to heterogeneity between them. Going forward, researchers of primary diagnostic studies should follow published guidelines for conducting and reporting their work to ensure that their efforts contribute to a high-quality evidence base (7, 11) .
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